(Q51568600)

7 April 2018

review article

1 reference

title

A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis. (English)

1 reference

7 April 2018

0 references

J P Devogelaer

1

1 reference

7 April 2018

publication date

1 August 1998

1 reference

7 April 2018

published in

Drug Safety

1 reference

7 April 2018

volume

19

1 reference

7 April 2018

issue

2

1 reference

7 April 2018

page(s)

141-154

1 reference

7 April 2018

Bone mass, bone loss, and osteoporosis prophylaxis

cites work

1 reference

12 December 2020

Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate

1 reference

12 December 2020

Long-lasting dermatological lesions after tiludronate therapy

1 reference

12 December 2020

Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause

1 reference

12 December 2020

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

12 December 2020

The clinical impact of vertebral fractures: quality of life in women with osteoporosis

1 reference

12 December 2020

Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy

1 reference

12 December 2020

Multiple ulcerative esophagitis caused by alendronate

1 reference

12 December 2020

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

1 reference

12 December 2020

Esophagitis associated with the use of alendronate

1 reference

12 December 2020

Bisphosphonate therapy of reflex sympathetic dystrophy syndrome

1 reference

12 December 2020

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

12 December 2020

Postmenopausal oestrogen treatment and stroke: a prospective study

1 reference

12 December 2020

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

1 reference

12 December 2020

Adverse effects of bisphosphonates. A comparative review

1 reference

12 December 2020

Treatment of postmenopausal osteoporosis with transdermal estrogen

1 reference

12 December 2020

The effect of postmenopausal estrogen therapy on bone density in elderly women

1 reference

12 December 2020

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

1 reference

12 December 2020

Responsiveness of endpoints in osteoporosis clinical trials

1 reference

12 December 2020

Extraskeletal effects of estrogen and the prevention of atherosclerosis

1 reference

12 December 2020

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

1 reference

12 December 2020

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo

1 reference

12 December 2020

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups

1 reference

12 December 2020

Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

1 reference

12 December 2020

Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin

1 reference

12 December 2020

Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome

1 reference

12 December 2020

Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone

1 reference

12 December 2020

Nonclinical model for assessing gastric effects of bisphosphonates

1 reference

12 December 2020

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

12 December 2020

Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment

1 reference

12 December 2020

Esophageal ulceration due to alendronate

1 reference

12 December 2020

Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women

1 reference

12 December 2020

Pamidronate: An unrecognized problem in gastrointestinal tolerability

1 reference

12 December 2020

Vitamin D3 and calcium to prevent hip fractures in elderly women

1 reference

12 December 2020

Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis

1 reference

12 December 2020

The risk of breast cancer after estrogen and estrogen-progestin replacement

1 reference

12 December 2020

Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women

1 reference

12 December 2020

Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss: do they exist?

1 reference

12 December 2020

Treatment of postmenopausal osteoporosis with calcitriol or calcium

1 reference

12 December 2020

Studies of the oral bioavailability of alendronate.

1 reference

12 December 2020

Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study

1 reference

12 December 2020

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

12 December 2020

Bone response to termination of oestrogen treatment

1 reference

12 December 2020

Perspective. How many women have osteoporosis?

1 reference

12 December 2020

Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis

1 reference

12 December 2020

Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial

1 reference

12 December 2020

Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy

1 reference

12 December 2020

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

12 December 2020

The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change.

1 reference

12 December 2020

Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae

1 reference

12 December 2020

Oesophageal stricture associated with alendronic acid

1 reference

12 December 2020

Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate

1 reference

12 December 2020

Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study

1 reference

12 December 2020

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

12 December 2020

Menopausal estrogen therapy and hip fractures

1 reference

12 December 2020

Low bone mineral content is common but osteoporotic fractures are rare in elderly rural Gambian women

1 reference

12 December 2020

A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers

1 reference

12 December 2020

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

1 reference

12 December 2020

Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group.

1 reference

12 December 2020

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

1 reference

12 December 2020

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial

1 reference

12 December 2020

Sustained response to intravenous alendronate in postmenopausal osteoporosis

1 reference

12 December 2020

Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis

1 reference

12 December 2020

Improper alendronate administration and a case of pill esophagitis

1 reference

12 December 2020

Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals

1 reference

12 December 2020

10.2165/00002018-199819020-00005

Identifiers

DOI

1 reference

7 April 2018

Dimensions Publication ID

1012526547

0 references

1 reference

7 April 2018